(Adnkronos) – "In recent years, we have seen an increase in the ability to effectively manage severe asthma thanks to advances in the development of new therapies, especially biological ones. Therapeutic innovation has made it possible to meet the needs of our patients, but critical issues remain." These were the words of Nicola Scichilone, president-elect of the Italian Respiratory Society (SIP-IRS), speaking at the Auditorium of the Ministry of Health in Rome during the conference promoted by the Longevitas Foundation.
"The new therapeutic arsenal must be guaranteed at all levels, ensuring equitable access for all patients. We must work together to break down barriers and advance innovation, meeting the needs of our patients first and foremost," he stated.
Although research advances now allow for increasingly effective management of severe asthma, according to Scichilone, "difficulties remain related to access to referral centers dedicated to the disease.
Access should be facilitated to intervene not only on patients' quality of life but also on the course and natural history of the disease itself."
For the president-elect of SIP-IRS, one of the main challenges remains treatment adherence. "What we ask and hope for is that more time be dedicated to our patients.
The time spent explaining the most appropriate and correct treatment must be considered a real phase in the treatment of the disease,” he concluded.
News
webinfo@adnkronos.com (Web Info)
